GS
Gilead Sciences, INC.
Concentrated strategyQuality / disciplined sizing
Total reported value
$2.1B
Reporting period: 2026-03-31 · Number of holdings: 6
GILEAD SCIENCES, INC. disclosed 6 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $2.1B and a quarterly turnover rate of 23.9%.
Personality snowflake
- Concentration
- 100
- Portfolio Stability
- 23.92
- Momentum/Contrarian
- 50
- Sector conviction
- 0
- Diversification
- 12
- Sizing Uniformity
- 90.38
Recent moves
Add ACLXGBX
0.0% $333.5M
Trim RCUS
0.0% -$70.1M
Trim LKFT
0.0% -$49.4M
Trim ASMB
0.0% -$28.2M
Trim KYTX
0.0% -$3.2M
Trim 98422T100
-92.9% -$359.5K
Holdings Map
New buyAddUnchangedTrim
Top 10 holdings by weight
Full holdings list this quarter
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx INC | Stock-Other | 36.44% | +13.80% | — | |
| 2 | RCUS | Arcus Biosciences INC | Stock-Other | 32.05% | -6.64% | — | |
| 3 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 23.67% | -4.78% | — | |
| 4 | ASMB | Assembly Biosciences INC | Stock-Other | 5.90% | -2.02% | — | |
| 5 | KYTX | Kyverna Therapeutics INC | Stock-Other | 1.68% | -0.32% | — | |
| 6 | ✓ | Xilio Therapeutics INC | Stock-Other | 0.26% | -0.04% | -92.86% |
Reported value over time
Sector allocation
Not enough sector-mapped data yet
Sector allocation over time
Quarterly history
Holding changes this quarter
Gilead Sciences, INC.'s most significant position changes for 2026-03-31: Trim: Xilio Therapeutics INC — shares -92.86%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ACLXGBX | Arcellx INC | +13.8% | — | Unchanged |
| 2 | ✓ | Xilio Therapeutics INC | 0% | -92.86% | Trim |
| 3 | KYTX | Kyverna Therapeutics INC | -0.3% | — | Unchanged |
| 4 | ASMB | Assembly Biosciences INC | -2% | — | Unchanged |
| 5 | LKFT | Lakefront Biotherapeutic-adr | -4.8% | — | Unchanged |
| 6 | RCUS | Arcus Biosciences INC | -6.6% | — | Unchanged |
FAQ
What is Gilead Sciences, INC. and what type of investor is it?
Gilead Sciences, INC. is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $2.1B, spread across 6 disclosed positions.
What are Gilead Sciences, INC.'s largest equity positions?
Based on the latest 13F filing, Gilead Sciences, INC.'s top holdings by market value are:
1. Arcellx INC (ACLXGBX) — $771.7M (36.4%)
2. Arcus Biosciences INC (RCUS) — $678.8M (32.0%)
3. Lakefront Biotherapeutic-adr (LKFT) — $501.2M (23.7%)
4. Assembly Biosciences INC (ASMB) — $125.0M (5.9%)
5. Kyverna Therapeutics INC (KYTX) — $35.6M (1.7%)
What changes did Gilead Sciences, INC. make in its most recent portfolio filing?
In the latest quarter, Gilead Sciences, INC. took a more defensive posture — trimming 1 positions and completely exiting 0 holdings. The largest of these moves: Trim: Xilio Therapeutics INC — shares -92.86%
What sectors does Gilead Sciences, INC. focus on?
Sector breakdown data is not yet available for Gilead Sciences, INC.. Check back after the next 13F processing cycle.